Co-Use of Opioid Medications and Alcohol Prevention Study (COAPS)
Project Number5R34AA029447-03
Former Number1R34AA029447-01
Contact PI/Project LeaderCOCHRAN, GERALD T. Other PIs
Awardee OrganizationUNIVERSITY OF UTAH
Description
Abstract Text
PUBLIC HEALTH ABSTRACT
Co-use of alcohol and opioid medications is known to be a serious health/safety hazard—yet persists
despite these negative ramifications. With limited information available within peer-reviewed literature, large-
scale system and clinical research have demonstrated 24-38% of those with alcohol use disorders also have an
opioid addiction, with rates of past 30-day opioid medication misuse among those seeking alcohol treatment as
high as 68%. Our research has shown that among community pharmacy patients receiving opioid medications
for pain management, approximately 20-30% are engaged in co-use of alcohol. Community pharmacy is a highly
valuable but underutilized resource and setting for identification and intervention to address the US opioid epi-
demic. We propose to adapt, manualize, and test the acceptability, feasibility, and preliminary efficacy of an
Alcohol-targeted Brief Intervention-Medication Therapy Management (ABI-MTM) intervention with community
pharmacy patients. ABI-MTM will be a pharmacy-based medication management intervention, combined with
Screening, Brief Intervention, and Referral to treatment that will target: (1) alcohol use elimination during opioid
treatment OR (2) non-opioid pain management substitution (in consultation with the prescriber). We will conduct
a small-scale trial in 3 community pharmacy locations wherein we will randomize patients with heavy alcohol use
and with non-heavy alcohol use (1-to-1 ratio) to ABI-MTM (n=20) or standard medication counseling (SMC,
n=20). Results will demonstrate intervention acceptability, feasibility, and preliminary efficacy. This study will also
work to identify pharmacy system and practice-level barriers and facilitators for universal alcohol screening and
intervention among opioid recipients. We will develop a mixed methods assessment guide to interview pharmacy
technicians (N=20), pharmacists (N=20), and corporate leaders (N=20). Interviews will assess perceptions to-
wards screening/intervention, internal organizational challenges, and processes related to ABI-MTM implemen-
tation for large-scale research and practice. Altogether, results of this study will provide critical insights, founda-
tional data, and strategies for executing a powered trial and possible future system/practice-level implementation.
Public Health Relevance Statement
NARRATIVE
Previous research, including that of our team, shows that a significant portion of those regularly using
opioids—particularly filling opioids at community pharmacies—also are involved in the co-use of alcohol. This
study proposes to adapt a previously developed intervention for opioid medication misuse; test its acceptability,
feasibility, and preliminary efficacy; and identify barriers and facilitators to large-scale research and system-level
implementation. Results of this study will directly inform a fully-powered subsequent multisite trial.
National Institute on Alcohol Abuse and Alcoholism
CFDA Code
273
DUNS Number
009095365
UEI
LL8GLEVH6MG3
Project Start Date
26-May-2022
Project End Date
30-April-2026
Budget Start Date
01-May-2024
Budget End Date
30-April-2026
Project Funding Information for 2024
Total Funding
$227,679
Direct Costs
$202,486
Indirect Costs
$25,193
Year
Funding IC
FY Total Cost by IC
2024
National Institute on Alcohol Abuse and Alcoholism
$227,679
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R34AA029447-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R34AA029447-03
Patents
No Patents information available for 5R34AA029447-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R34AA029447-03
Clinical Studies
No Clinical Studies information available for 5R34AA029447-03
News and More
Related News Releases
No news release information available for 5R34AA029447-03
History
No Historical information available for 5R34AA029447-03
Similar Projects
No Similar Projects information available for 5R34AA029447-03